Novo Nordisk Receives FDA Approval For Vagifem
Novo Nordisk has received FDA has approval for 10mcg dose formulation of Vagifem (estradiol vaginal tablets) for the treatment of atrophic vaginitis due to menopause. The approval makes
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.
Sanofi-aventis has entered into an exclusive global licensing agreement with the Rockefeller University, New York, for a monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal
AstraZeneca and Targacept have entered into a collaboration and license agreement for the global development and commercialisation of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).